Health care stocks were softer Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each declining about 0.2%.
The iShares Biotechnology ETF (IBB) eased 0.1%.
In corporate news, CVS Health (CVS) reported better-than-expected Q4 results and projected higher 2025 earnings. The shares jumped about 16%.
Biogen (BIIB) guided for a decline in earnings and revenue for 2025 amid ongoing challenges in its multiple sclerosis product category, despite reporting stronger-than-expected Q4 results. Its shares fell 5.7%.
NKGen Biotech (NKGN) shares jumped 37% after it said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.